Dateline City:
WALTHAM, Mass. and KENILWORTH, N.J.
Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma
WALTHAM, Mass. and KENILWORTH, N.J. Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndaxs entinostat in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma.
Language:
English
read more